Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience

@inproceedings{Coppo2010PredictiveFO,
  title={Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience},
  author={Paul Coppo and Michael Schwarzinger and Marc Buffet and Alain Wynckel and Karine Clabault and Claire Presne and Pascale Poullin and Sandrine Malot and Philippe Vanhille and Elie Azoulay and Lionel Galicier and Virginie Lemiale and J -C Mira and Christophe Ridel and Eric Rondeau and Jacques Pourrat and St{\'e}phane Girault and Dominique Bordessoule and Samir Saheb and Michel Ramakers and Mohamed Amine Hamidou and J Vernant and Bertrand Guidet and Martine Wolf and Agn{\`e}s Veyradier},
  booktitle={PloS one},
  year={2010}
}
Severe ADAMTS13 deficiency occurs in 13% to 75% of thrombotic microangiopathies (TMA). In this context, the early identification of a severe, antibody-mediated, ADAMTS13 deficiency may allow to start targeted therapies such as B-lymphocytes-depleting monoclonal antibodies. To date, assays exploring ADAMTS13 activity require skill and are limited to only… CONTINUE READING